Prediction of drug-related cardiac adverse effects in humans-A: Creation of a database of effects and identification of factors affecting their occurrence

Regulatory Toxicology and Pharmacology

Volumn 56, Issue 3, 2010, Pages 247-275

  Matthews, Edwin J ^a   Frid, Anna A ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b GlobalNet Services   (United States)

Author keywords

AERS; BioEpisteme ; Clinical indication; Drug induced cardiac toxicity; Drug related adverse effect; In silico; Mechanism of action; MedDRA; QSAR; Quantitative structure activity relationships; SRS; Therapeutic target

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR LIGAND; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE UPTAKE INHIBITOR; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN 1D ANTAGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACCURACY; ARTICLE; BRADYCARDIA; CARDIOTOXICITY; COMPUTER PREDICTION; COMPUTER PROGRAM; CORONARY ARTERY DISEASE; DATA BASE; DRUG EFFICACY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PALPITATION; HEART RATE; HEART RHYTHM; HUMAN; INFORMATION PROCESSING; MYOCARDIAL DISEASE; PRIORITY JOURNAL; PURKINJE CELL; QT PROLONGATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TACHYCARDIA; TORSADE DES POINTES; VALVULAR HEART DISEASE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CARDIOVASCULAR DISEASES; CLUSTER ANALYSIS; DATABASES, FACTUAL; DRUG LABELING; DRUG TOXICITY; FORECASTING; HEART; HUMANS; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING; PURKINJE FIBERS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOFTWARE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77249096313     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2009.11.006     Document Type: Article

References (17)

1. Almenoff J.S., LaCroix K.K., Yuen N.A., Fram D., and DuMouchel W. Comparative performance of two quantitative safety signaling methods. Drug Safety 29 (2006) 875-887
2. Combs A.B., and Acosta D. In: Ekins S. (Ed). Computational Toxicology. Risk Assessment for Pharmaceuticals and Environmental Chemicals (2006), Wiley Interscience, New York 3-20
3. Combs A.B., Ramos K., and Acosta D. Cardiovascular toxicity. In: Hodgen E., and Smart R.C. (Eds). Introduction to Biochemical Toxicity. 3rd ed. (2001), Wiley Interscience, New York 673-696
4. Cooper J.A., Saracci R., and Cole P. Describing the validity of carcinogen screening tests. Brit. J. Cancer 39 (1979) 87-89
5. COSTART. Coding Symbols for Thesaurus of Adverse Reaction Terms, 5th ed., Department of Health and Human Services: Rockville, MD, 1995.
6. Curren M.E., Splawski I., Timothy K.W., Wincent G.M., Green E.D., and Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80 (1995) 795-803
7. Evans S.J., Waller P.C., and Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Safety 10 (2001) 483-486
8. Frid A.A., and Matthews E.J. Prediction of drug-related cardiac adverse effects in humans-B: Use of QSAR systems for early detection of drug-induced cardiac toxicities. Regul. Toxicol. Pharmacol. 56 (2010) 276-289
9. Fung M., Thornton A., Mybeck K., Wu J.H., Hornbuckle K., and Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Inform. J. 25 (2001) 293-317
10. Matthews E.J., and Contrera J.F. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. Regul. Toxicol. Pharmacol. 28 (1998) 242-264
11. Matthews E.J., Kruhlak N.L., Weaver J.L., Benz R.D., and Contrera J.F. Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Curr. Drug Discov. Technol. I (2004) 243-254
12. Matthews E.J., and Contrera J.F. In silico approaches to explore toxicity end points: issues and concerns for estimating human health effects. Expert Opin. Drug Metab. Toxicol. 3 (2007) 125-134
13. Matthews E.J., Kruhlak N.L., Benz R.D., Aragonés Sabaté D., Marchant C.A., and Contrera J.F. Identification of structure activity relationships for adverse effects of pharmaceuticals in humans: C. Use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities. Regul. Toxicol. Pharmacol. 54 (2009) 43-65
14. Matthews E.J., Ursem C.J., Kruhlak N.L., Benz R.D., Aragonés Sabaté D., Yang C., Klopman G., and Contrera J.F. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: B. Use of QSAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. Regul. Toxicol. Pharmacol. 54 (2009) 23-42
15. Moore N., Thiessard F., and Begaud B. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. Pharmacoepidemeol. Drug Safety 14 (2005) 285-286
16. Pan S.J., Combs A.B., and Acosta D. Emetine inhibits glycolysis in isolated, perfused rat hearts. Cardiovasc. Toxicol. 3 (2001) 311-318
17. Ursem C.J., Matthews E.J., Kruhlak N.L., Contrera J.F., and Benz R.D. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans A: use of FDA post market reports to create a database of hepatobiliary and urinary tract toxicities. Regul. Toxicol. Pharmacol. 54 (2009) 1-22